Home LiteratureArticle Details
PMID: 22236449 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease.

NeuroImage ·Vol. 60 ·No. 1 ·2012-03-00 ·Pages 221-9

Gray KR, Wolz R, Heckemann RA, Aljabar P, Hammers A, Rueckert D, Alzheimer's Disease Neuroimaging Initiative

Abstract

Imaging biomarkers for Alzheimer's disease are desirable for improved diagnosis and monitoring, as well as drug discovery. Automated image-based classification of individual patients could provide valuable diagnostic support for clinicians, when considered alongside cognitive assessment scores. We investigate the value of combining cross-sectional and longitudinal multi-region FDG-PET information for classification, using clinical and imaging data from the Alzheimer's Disease Neuroimaging Initiative. Whole-brain segmentations into 83 anatomically defined regions were automatically generated for baseline and 12-month FDG-PET images. Regional signal intensities were extracted at each timepoint, as well as changes in signal intensity over the follow-up period. Features were provided to a support vector machine classifier. By combining 12-month signal intensities and changes over 12 months, we achieve significantly increased classification performance compared with using any of the three feature sets independently. Based on this combined feature set, we report classification accuracies of 88% between patients with Alzheimer's disease and elderly healthy controls, and 65% between patients with stable mild cognitive impairment and those who subsequently progressed to Alzheimer's disease. We demonstrate that information extracted from serial FDG-PET through regional analysis can be used to achieve state-of-the-art classification of diagnostic groups in a realistic multi-centre setting. This finding may be usefully applied in the diagnosis of Alzheimer's disease, predicting disease course in individuals with mild cognitive impairment, and in the selection of participants for clinical trials.

MeSH Terms
Aged Alzheimer Disease/classification,diagnostic imaging Female Fluorodeoxyglucose F18 Humans Male Positron-Emission Tomography/methods Radiopharmaceuticals
Chemicals
Radiopharmaceuticals Fluorodeoxyglucose F18
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Gray Katherine R
Biomedical Image Analysis Group, Department of Computing, Imperial College London, UK. [email protected]
Wolz Robin
Heckemann Rolf A
Aljabar Paul
Hammers Alexander
Rueckert Daniel
Alzheimer's Disease Neuroimaging Initiative
References (47)
47 references, click to expand
  1. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe.
    Hum Brain Mapp. 2003 Aug;19(4):224-47 PMID: 12874777
  2. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.
    J Nucl Med. 2008 Mar;49(3):390-8 PMID: 18287270
  3. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data.
    Neuroimage. 2006 Apr 1;30(2):436-43 PMID: 16300968
  4. Nonrigid registration using free-form deformations: application to breast MR images.
    IEEE Trans Med Imaging. 1999 Aug;18(8):712-21 PMID: 10534053
  5. Mild cognitive impairment: clinical characterization and outcome.
    Arch Neurol. 1999 Mar;56(3):303-8 PMID: 10190820
  6. Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation.
    Neuroimage. 2010 May 15;51(1):221-7 PMID: 20114079
  7. FDG PET imaging in patients with pathologically verified dementia.
    J Nucl Med. 2000 Nov;41(11):1920-8 PMID: 11079505
  8. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment.
    Ann Neurol. 2003 Sep;54(3):343-51 PMID: 12953266
  9. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Neuroimage. 2009 May 1;45(4):1107-16 PMID: 19349228
  10. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement. 2011 May;7(3):263-9 PMID: 21514250
  11. Automatic morphometry in Alzheimer's disease and mild cognitive impairment.
    Neuroimage. 2011 Jun 15;56(4):2024-37 PMID: 21397703
  12. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18.
    Psychiatry Res. 2008 Nov 30;164(2):143-53 PMID: 18930634
  13. Mild cognitive impairment as a diagnostic entity.
    J Intern Med. 2004 Sep;256(3):183-94 PMID: 15324362
  14. A nonparametric method for automatic correction of intensity nonuniformity in MRI data.
    IEEE Trans Med Imaging. 1998 Feb;17(1):87-97 PMID: 9617910
  15. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans.
    Comput Methods Programs Biomed. 1997 May;53(1):15-25 PMID: 9113464
  16. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement. 2011 May;7(3):270-9 PMID: 21514249
  17. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.
    Neuroimage. 2002 Sep;17(1):302-16 PMID: 12482085
  18. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71 PMID: 11526211
  19. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.
    Ann Neurol. 2001 Sep;50(3):358-65 PMID: 11558792
  20. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage. 2010 Jun;51(2):654-64 PMID: 20202480
  21. Genetic algorithm-based PCA eigenvector selection and weighting for automated identification of dementia using FDG-PET imaging.
    Annu Int Conf IEEE Eng Med Biol Soc. 2008;2008:4812-5 PMID: 19163793
  22. Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database.
    Neuroimage. 2011 May 15;56(2):766-81 PMID: 20542124
  23. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.
    Neurology. 2005 Jun 14;64(11):1860-7 PMID: 15955934
  24. Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation.
    Neuroimage. 2009 Jul 1;46(3):749-61 PMID: 19236922
  25. Forecasting the global burden of Alzheimer's disease.
    Alzheimers Dement. 2007 Jul;3(3):186-91 PMID: 19595937
  26. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease.
    Arch Neurol. 2005 Nov;62(11):1728-33 PMID: 16286547
  27. Comparison of phantom and registration scaling corrections using the ADNI cohort.
    Neuroimage. 2009 Oct 1;47(4):1506-13 PMID: 19477282
  28. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
    J Magn Reson Imaging. 2008 Apr;27(4):685-91 PMID: 18302232
  29. Multimodal classification of Alzheimer's disease and mild cognitive impairment.
    Neuroimage. 2011 Apr 1;55(3):856-67 PMID: 21236349
  30. Automated hippocampal segmentation by regional fluid registration of serial MRI: validation and application in Alzheimer's disease.
    Neuroimage. 2001 May;13(5):847-55 PMID: 11304081
  31. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM).
    Neuroimage. 1995 Jun;2(2):89-101 PMID: 9343592
  32. Feature selection using factor analysis for Alzheimer's diagnosis using 18F-FDG PET images.
    Med Phys. 2010 Nov;37(11):6084-95 PMID: 21158320
  33. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    JAMA. 2001 Nov 7;286(17):2120-7 PMID: 11694153
  34. Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset.
    Neuroimage. 2009 Oct 15;48(1):138-49 PMID: 19481161
  35. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization.
    Neuroimage. 2009 Jul 15;46(4):981-8 PMID: 19303935
  36. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
    Neurology. 2004 Dec 28;63(12):2332-40 PMID: 15623696
  37. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.
    Alzheimers Dement. 2010 May;6(3):221-9 PMID: 20451870
  38. Neural-network classification of normal and Alzheimer's disease subjects using high-resolution and low-resolution PET cameras.
    J Nucl Med. 1994 Jan;35(1):7-15 PMID: 8271062
  39. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging.
    Neuroimage. 2009 Jan 1;44(1):43-50 PMID: 18691659
  40. Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI).
    Dement Geriatr Cogn Disord. 2009;28(3):259-66 PMID: 19786778
  41. Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population.
    Neuroimage. 2011 Mar 15;55(2):574-89 PMID: 21146621
  42. Unified segmentation.
    Neuroimage. 2005 Jul 1;26(3):839-51 PMID: 15955494
  43. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest.
    Neuroimage. 2008 Apr 1;40(2):672-684 PMID: 18234511
  44. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement. 2011 May;7(3):280-92 PMID: 21514248
  45. Brain MAPS: an automated, accurate and robust brain extraction technique using a template library.
    Neuroimage. 2011 Apr 1;55(3):1091-108 PMID: 21195780
  46. Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years.
    Am J Geriatr Psychiatry. 2008 May;16(5):384-8 PMID: 18448850
  47. Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI.
    Neuroimage. 2010 Aug 1;52(1):109-18 PMID: 20382238
Article Info
Journal
NeuroImage
Abbr.
Neuroimage
ISSN
1095-9572
Published
2012-03-00
Epub
2012-00-06
Pages
221-9
Language
English
Region
United States
NLM ID
9215515
PMCID
PMC3303084
Subset
IM
Grants
NIA NIH HHS · K01 AG030514 · United States
NIA NIH HHS · U01 AG024904-01 · United States
Medical Research Council · G108/585 · United Kingdom
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · K01 AG030514-01A1 · United States
The Dunhill Medical Trust · R62/1107 · United Kingdom
NIA NIH HHS · P30 AG010129-09 · United States
NIA NIH HHS · P30 AG010129 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]